# Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

> **NCT03539900** · PHASE2,PHASE3 · COMPLETED · sponsor: **Yale University** · enrollment: 89 (actual)

## Conditions studied

- Binge-Eating Disorder

## Interventions

- **DRUG:** Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03539900
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-17
- **Primary completion:** 2022-04-19
- **Final completion:** 2023-03-22
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2024-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03539900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03539900, "Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT03539900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*